Physician profile
Nilay Shah
NPI 1154372621
$415,409.88
in general payments reported to CMS, 2019-2025
65 companies · $57K in 2025
The $57K reported for 2025 was more than what 97% of Clinical Neurophysiology providers received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $36K · 2021: $25K · 2022: $55K · 2023: $109K · 2024: $108K · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $196K · Honoraria: $30K · Travel and Lodging: $28K · Food and Beverage: $15K · Consulting Fee: $4,000 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $770 · Education: $34.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $196,367.20 |
| Honoraria | $29,550.00 |
| Travel and Lodging | $27,536.62 |
| Food and Beverage | $15,412.38 |
| Consulting Fee | $4,000.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $770.00 |
| Education | $34.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $195,528.51 | 2019-2024 | Mavenclad, Mavenclad |
| Tg Therapeutics, INC. | $120,857.09 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $32,423.68 | 2020-2025 | Zeposia |
| Sk Life Science, INC. | $27,021.63 | 2020-2025 | Xcopri |
| Ani Pharmaceuticals, INC. | $7,895.95 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $5,346.39 | 2019 | |
| Kedrion Biopharma, INC. | $4,000.00 | 2024-2025 | Rhogam Ultra-Filtered Plus, Albuked, Kedrab |
| Celgene Corporation | $3,837.86 | 2021-2025 | Zeposia |
| Janssen Pharmaceuticals, INC | $2,614.67 | 2020-2022 | |
| Abbott Laboratories | $1,433.19 | 2020-2023 | Infinity |
| Biogen, INC. | $1,393.70 | 2019-2025 | Vumerity, Tysabri |
| Novartis Pharmaceuticals Corporation | $1,202.27 | 2019-2025 | |
| Livanova USA, INC. | $941.98 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $867.15 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $771.38 | 2019-2023 | Qulipta, Ubrelvy, Vraylar |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cadwell Industries, INC | $770.00 | 2024 | |
| Banner Life Sciences, LLC | $750.00 | 2022 | |
| Boston Scientific Corporation | $609.09 | 2019-2023 | |
| Neurelis, INC. | $506.76 | 2020-2025 | Valtoco |
| Csl Behring | $458.52 | 2019-2025 | Hizentra |
| Neurocrine Biosciences, INC. | $455.97 | 2021-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $439.68 | 2021-2025 | |
| Axsome Therapeutics, INC. | $431.85 | 2025 | Symbravo |
| Mallinckrodt Hospital Products INC. | $378.83 | 2020-2025 | Acthar |
| Eisai INC. | $374.14 | 2019-2024 | |
| Genzyme Corporation | $371.38 | 2019-2023 | |
| Argenx US, INC. | $306.21 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Amgen INC. | $280.06 | 2019-2025 | Uplizna |
| Lilly USA, LLC | $252.32 | 2019-2024 | Reyvow, Emgality, Amyvid |
| Mdd US Operations, LLC | $228.20 | 2021-2025 | Apokyn, Apokyn, Xadago |
| Allergan, INC. | $188.22 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $186.30 | 2021 | |
| Vanda Pharmaceuticals INC. | $164.54 | 2025 | Ponvory |
| Jazz Pharmaceuticals INC. | $156.94 | 2023-2025 | |
| Strongbridge US INC. | $146.23 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $135.47 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $120.72 | 2021-2025 | Keveyis |
| Lundbeck LLC | $117.28 | 2023-2025 | Vyepti |
| Stryker Corporation | $110.74 | 2021 | |
| Amneal Pharmaceuticals LLC | $100.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.43 | 2023-2025 | Hyqvia |
| Sunovion Pharmaceuticals INC. | $98.51 | 2019-2021 | |
| Medtronic, INC. | $94.37 | 2022 | |
| Adamas Pharmaceuticals, INC. | $82.03 | 2021 | |
| Arbor Pharmaceuticals, INC. | $81.40 | 2020-2022 | |
| Ucb, INC. | $79.94 | 2020-2024 | Briviact |
| Ge Healthcare | $79.58 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $75.82 | 2022 | |
| Acorda Therapeutics, INC | $63.05 | 2019-2022 | |
| Genentech USA, INC. | $60.00 | 2019-2025 | Ocrevus Zunovo |
| Vertical Pharmaceuticals, LLC | $55.06 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $52.70 | 2023-2024 | Rexulti, Nuedexta |
| Grifols USA, LLC | $52.62 | 2020-2025 | Gamunex-C |
| Alexion Pharmaceuticals, INC. | $49.12 | 2019-2025 | Ultomiris |
| Collegium Pharmaceutical, INC. | $38.17 | 2022 | |
| Kyowa Kirin, INC. | $32.91 | 2023 | Nourianz |
| Octapharma USA, INC. | $28.94 | 2022 | |
| Biotronik Nro, INC. | $20.93 | 2025 | Prospera |
| Tolmar, INC. | $17.18 | 2024 | |
| Corium, LLC | $16.61 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $15.11 | 2023 | Prehevbrio |
| Bausch Health US, LLC | $14.73 | 2019 | |
| Merz Pharmaceuticals, LLC | $13.44 | 2022 | |
| Horizon Therapeutics Plc | $13.33 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,311.06 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nilay Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.